Globus Medical (NYSE:GMED - Get Free Report) updated its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share guidance of 4.950-5.050 for the period, compared to the consensus earnings per share estimate of 4.740. The company issued revenue guidance of $3.2 billion-$3.2 billion, compared to the consensus revenue estimate of $3.2 billion.
Wall Street Analysts Forecast Growth
A number of equities analysts have commented on the stock. BMO Capital Markets started coverage on shares of Globus Medical in a research report on Wednesday, July 8th. They issued an "outperform" rating and a $94.00 price target on the stock. Weiss Ratings reiterated a "hold (c+)" rating on shares of Globus Medical in a research note on Monday, July 13th. Stifel Nicolaus reduced their target price on Globus Medical from $95.00 to $80.00 and set a "hold" rating on the stock in a report on Wednesday, July 8th. Truist Financial decreased their price target on Globus Medical from $115.00 to $100.00 and set a "buy" rating on the stock in a research report on Thursday, July 16th. Finally, Needham & Company LLC raised their price target on Globus Medical from $114.00 to $117.00 and gave the company a "buy" rating in a report on Friday, May 8th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $102.08.
Check Out Our Latest Stock Report on GMED
Globus Medical Stock Performance
Shares of NYSE GMED traded up $0.72 during trading on Thursday, reaching $81.26. The company had a trading volume of 2,195,988 shares, compared to its average volume of 1,487,304. Globus Medical has a 52 week low of $52.69 and a 52 week high of $101.40. The business's 50 day moving average price is $79.35 and its 200-day moving average price is $85.34. The stock has a market cap of $11.03 billion, a PE ratio of 18.90, a PEG ratio of 1.68 and a beta of 0.95.
Globus Medical (NYSE:GMED - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The medical device company reported $1.34 EPS for the quarter, beating the consensus estimate of $1.10 by $0.24. The business had revenue of $789.61 million for the quarter, compared to analysts' expectations of $782.88 million. Globus Medical had a net margin of 18.92% and a return on equity of 13.46%. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. Equities analysts anticipate that Globus Medical will post 4.74 earnings per share for the current year.
Insider Buying and Selling
In other news, Director David D. Davidar sold 25,000 shares of Globus Medical stock in a transaction on Friday, June 5th. The stock was sold at an average price of $80.76, for a total value of $2,019,000.00. Following the completion of the sale, the director directly owned 510,175 shares of the company's stock, valued at approximately $41,201,733. This trade represents a 4.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 18.38% of the company's stock.
Institutional Trading of Globus Medical
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Parallel Advisors LLC increased its stake in Globus Medical by 45.1% in the third quarter. Parallel Advisors LLC now owns 557 shares of the medical device company's stock valued at $32,000 after acquiring an additional 173 shares during the last quarter. EverSource Wealth Advisors LLC lifted its stake in Globus Medical by 74.3% during the second quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company's stock worth $27,000 after purchasing an additional 197 shares during the last quarter. Mindset Wealth Management LLC boosted its holdings in shares of Globus Medical by 1.9% in the 4th quarter. Mindset Wealth Management LLC now owns 10,715 shares of the medical device company's stock valued at $936,000 after purchasing an additional 200 shares in the last quarter. Northwestern Mutual Wealth Management Co. boosted its holdings in shares of Globus Medical by 33.4% in the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 999 shares of the medical device company's stock valued at $57,000 after purchasing an additional 250 shares in the last quarter. Finally, Wealthspire Advisors LLC increased its stake in shares of Globus Medical by 11.4% in the 4th quarter. Wealthspire Advisors LLC now owns 2,645 shares of the medical device company's stock valued at $231,000 after purchasing an additional 271 shares during the last quarter. 95.16% of the stock is owned by institutional investors.
About Globus Medical
(
Get Free Report)
Globus Medical, Inc NYSE: GMED is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.
In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Globus Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Globus Medical wasn't on the list.
While Globus Medical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
